NCT04479449View on ClinicalTrials.gov

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

October 19, 2020

Study Completion Date

December 18, 2020

Conditions
Ischemic Stroke
Interventions
DRUG

SP-8203

SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)

DRUG

Placebo

Placebo will be intravenously administered twice daily (intervals of 12 hours)

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

NCT04479449 - Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA | Biotech Hunter | Biotech Hunter